The choreography of HIV-1 proteolytic processing and virion assembly

Journal of Biological Chemistry

Volumn 287, Issue 49, 2012, Pages 40867-40874

  Lee, Sook Kyung ^a,b   Potempa, Marc ^a   Swanstrom, Ronald ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL LEVEL; CELLULAR TARGETS; ENZYMATIC ACTIVITIES; HOST PROTEINS; INTEGRASE; INTENSIVE RESEARCH; NUCLEOCAPSIDS; PROTEIN-BINDING; PROTEIN-CODING; PROTEIN-PROTEIN INTERACTIONS; PROTEOLYTIC PROCESSING; REVERSE TRANSCRIPTASES; RNASE H; STRUCTURAL PROTEINS; VIRAL GENOME; VIRAL LIFE CYCLE; VIRAL PROTEASE; VIRAL PROTEINS; VIRAL REPLICATION;

ENZYME ACTIVITY; GENES; PEPTIDES;

VIRUSES;

CHEMOKINE RECEPTOR CCR5; GAG PROTEIN; PROTEIN PRECURSOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; STRUCTURAL PROTEIN; VIRUS DNA; VIRUS ENZYME; VIRUS PROTEIN;

BINDING AFFINITY; CHOREOGRAPHY; CRYSTAL STRUCTURE; DNA SYNTHESIS; ENZYME ACTIVITY; ENZYME SUBSTRATE; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DEGRADATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SHORT SURVEY; VIRUS ASSEMBLY; VIRUS GENOME; VIRUS MORPHOLOGY; VIRUS PARTICLE; VIRUS REPLICATION;

CATALYTIC DOMAIN; DRUG RESISTANCE; GENE EXPRESSION REGULATION, VIRAL; GENE PRODUCTS, GAG; GENOME, VIRAL; HIV-1; HUMANS; MODELS, GENETIC; MOLECULAR CONFORMATION; MUTATION; PROTEASE INHIBITORS; PROTEIN INTERACTION MAPPING; PROTEOLYSIS; RECEPTORS, CCR5; VIRION; VIRUS ASSEMBLY; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; MIRIDAE;

EID: 84870340629     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.R112.399444     Document Type: Short Survey

References (101)

1. Bieniasz, P. D. (2009) The cell biology of HIV-1 virion genesis. Cell Host Microbe 5, 550-558
2. Weiss, E. R., and Göttlinger, H. (2011) The role of cellular factors in promoting HIV budding. J. Mol. Biol. 410, 525-533
3. Sundquist, W. I., and Krausslich, H. G. (2012) HIV-1 Assembly, Budding, and Maturation. Cold Spring Harb. Perspect. Med. 2, a006924
4. Carlson, L. A., Briggs, J. A., Glass, B., Riches, J. D., Simon, M. N., Johnson, M. C., Müller, B., Grünewald, K., and Kräusslich, H. G. (2008) Three-dimensional analysis of budding sites and released virus suggests a revised model for HIV-1 morphogenesis. Cell Host Microbe 4, 592-599 (Pubitemid 352762957)
5. Jacks, T. (1990) Translational suppression in gene expression in retroviruses and retrotransposons. Curr. Top. Microbiol. Immunol. 157, 93-124
6. Swanstrom, R., and Wills, J. W. (1997) in Retroviruses (Coffin, J. M., Hughes, S. H., and Varmus, H. E., ed) pp. 263-334, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
7. Briggs, J. A., Simon, M. N., Gross, I., Kräusslich, H. G., Fuller, S. D., Vogt, V. M., and Johnson, M. C. (2004) The stoichiometry of Gag protein in HIV-1. Nat. Struct. Mol. Biol. 11, 672-675 (Pubitemid 38823535)
8. Ambrose, Z., Julias, J. G., Boyer, P. L., Kewalramani, V. N., and Hughes, S. H. (2006) The level of reverse transcriptase (RT) in human immunodeficiency virus type 1 particles affects susceptibility to nonnucleoside RT inhibitors but not to lamivudine. J. Virol. 80, 2578-2581 (Pubitemid 43271563)
9. Shen, L., Peterson, S., Sedaghat, A. R., McMahon, M. A., Callender, M., Zhang, H., Zhou, Y., Pitt, E., Anderson, K. S., Acosta, E. P., and Siliciano, R. F. (2008) Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat. Med. 14, 762-766 (Pubitemid 351951518)
10. Sampah, M. E., Shen, L., Jilek, B. L., and Siliciano, R. F. (2011) Doseresponse curve slope is a missing dimension in the analysis of HIV-1 drug resistance. Proc. Natl. Acad. Sci. U.S.A. 108, 7613-7618
11. Shen, L., Rabi, S. A., Sedaghat, A. R., Shan, L., Lai, J., Xing, S., and Siliciano, R. F. (2011) A critical subset model provides a conceptual basis for the high antiviral activity of major HIV drugs. Sci. Transl. Med. 3, 91ra63
12. de la Carrière, L. C., Paulous, S., Clavel, F., and Mammano, F. (1999) Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity. J. Virol. 73, 3455-3459
13. Henderson, G. J., Lee, S. K., Irlbeck, D. M., Harris, J., Kline, M., Pollom, E., Parkin, N., and Swanstrom, R. (2012) Interplay between single resistance-associated mutations in the HIV-1 protease and viral infectivity, protease activity, and inhibitor sensitivity. Antimicrob. Agents Chemother. 56, 623-633
14. Boyer, P. L., Sarafianos, S. G., Arnold, E., and Hughes, S. H. (2001) Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J. Virol. 75, 4832-4842 (Pubitemid 32381526)
15. Tong, W., Lu, C. D., Sharma, S. K., Matsuura, S., So, A. G., and Scott, W. A. (1997) Nucleotide-induced stable complex formation by HIV-1 reverse transcriptase. Biochemistry 36, 5749-5757 (Pubitemid 27214926)
16. Meyer, P. R., Matsuura, S. E., Mian, A. M., So, A. G., and Scott, W. A. (1999) A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol. Cell 4, 35-43 (Pubitemid 29386129)
17. Jouvenet, N., Simon, S. M., and Bieniasz, P. D. (2009) Imaging the interaction of HIV-1 genomes and Gag during assembly of individual viral particles. Proc. Natl. Acad. Sci. U.S.A. 106, 19114-19119
18. Ivanchenko, S., Godinez, W. J., Lampe, M., Kräusslich, H. G., Eils, R., Rohr, K., Bräuchle, C., Müller, B., and Lamb, D. C. (2009) Dynamics of HIV-1 assembly and release. PLoS Pathog. 5, e1000652
19. Kutluay, S. B., and Bieniasz, P. D. (2010) Analysis of the initiating events in HIV-1 particle assembly and genome packaging. PLoS Pathog. 6, e1001200
20. Ganser-Pornillos, B. K., Yeager, M., and Pornillos, O. (2012) Assembly and architecture of HIV. Adv. Exp. Med. Biol. 726, 441-465
21. Lefebvre, E., and Schiffer, C. A. (2008) Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. AIDS Rev. 10, 131-142
22. Agniswamy, J., Sayer, J. M., Weber, I. T., and Louis, J. M. (2012) Terminal interface conformations modulate dimer stability prior to amino-terminal autoprocessing of HIV-1 protease. Biochemistry 51, 1041-1050
23. Louis, J. M., Clore, G. M., and Gronenborn, A. M. (1999) Autoprocessing of HIV-1 protease is tightly coupled to protein folding. Nat. Struct. Biol. 6, 868-875 (Pubitemid 29415180)
24. Huang, L., Li, Y., and Chen, C. (2011) Flexible catalytic site conformations implicated in modulation of HIV-1 protease autoprocessing reactions. Retrovirology 8, 79
25. Tang, C., Louis, J. M., Aniana, A., Suh, J. Y., and Clore, G. M. (2008) Visualizing transient events in amino-terminal autoprocessing of HIV-1 protease. Nature 455, 693-696
26. Pettit, S. C., Gulnik, S., Everitt, L., and Kaplan, A. H. (2003) The dimer interfaces of protease and extra-protease domains influence the activation of protease and the specificity of Gag-Pol cleavage. J. Virol. 77, 366-374 (Pubitemid 36004976)
27. Ludwig, C., Leiherer, A., and Wagner, R. (2008) Importance of protease cleavage sites within and flanking human immunodeficiency virus type 1 transframe protein p6*for spatiotemporal regulation of protease activation. J. Virol. 82, 4573-4584 (Pubitemid 351563694)
28. Pettit, S. C., Everitt, L. E., Choudhury, S., Dunn, B. M., and Kaplan, A. H. (2004) Initial cleavage of the human immunodeficiency virus type 1 Gag-Pol precursor by its activated protease occurs by an intramolecular mechanism. J. Virol. 78, 8477-8485 (Pubitemid 39025113)
29. Erickson-Viitanen, S., Manfredi, J., Viitanen, P., Tribe, D. E., Tritch, R., Hutchison, C. A., 3rd, Loeb, D. D., and Swanstrom, R. (1989) Cleavage of HIV-1 Gag polyprotein synthesized in vitro: sequential cleavage by the viral protease. AIDS Res. Hum. Retroviruses 5, 577-591 (Pubitemid 20055070)
30. Pettit, S. C., Lindquist, J. N., Kaplan, A. H., and Swanstrom, R. (2005) Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates. Retrovirology 2, 66
31. Pettit, S. C., Moody, M. D., Wehbie, R. S., Kaplan, A. H., Nantermet, P. V., Klein, C. A., and Swanstrom, R. (1994) The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J. Virol. 68, 8017-8027 (Pubitemid 24362690)
32. Wiegers, K., Rutter, G., Kottler, H., Tessmer, U., Hohenberg, H., and Kräusslich, H. G. (1998) Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. J. Virol. 72, 2846-2854 (Pubitemid 28175521)
33. Lee, S. K., Harris, J., and Swanstrom, R. (2009) A strongly transdominant mutation in the human immunodeficiency virus type 1 gag gene defines an Achilles heel in the virus life cycle. J. Virol. 83, 8536-8543
34. Müller, B., Anders, M., Akiyama, H., Welsch, S., Glass, B., Nikovics, K., Clavel, F., Tervo, H. M., Keppler, O. T., and Kräusslich, H. G. (2009) HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity. J. Biol. Chem. 284, 29692-29703
35. Tritch, R. J., Cheng, Y. E., Yin, F. H., and Erickson-Viitanen, S. (1991) Mutagenesis of protease cleavage sites in the human immunodeficiency virus type 1 Gag polyprotein. J. Virol. 65, 922-930
36. Pettit, S. C., Simsic, J., Loeb, D. D., Everitt, L., Hutchison, C. A., 3rd, and Swanstrom, R. (1991) Analysis of retroviral protease cleavage sites reveals two types of cleavage sites and the structural requirements of the P1 amino acid. J. Biol. Chem. 266, 14539-14547 (Pubitemid 21907537)
37. Prabu-Jeyabalan, M., Nalivaika, E., and Schiffer, C. A. (2002) Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure 10, 369-381 (Pubitemid 34230624)
38. Ozen, A., Haliloǧlu, T., and Schiffer, C. A. (2011) Dynamics of preferential substrate recognition in HIV-1 protease: redefining the substrate envelope. J. Mol. Biol. 410, 726-744
39. Jouvenet, N., Bieniasz, P. D., and Simon, S. M. (2008) Imaging the biogenesis of individual HIV-1 virions in live cells. Nature 454, 236-240 (Pubitemid 351969887)
40. Kräusslich, H. G. (1991) Human immunodeficiency virus proteinase dimer as component of the viral polyprotein prevents particle assembly and viral infectivity. Proc. Natl. Acad. Sci. U.S.A. 88, 3213-3217
41. Ott, D. E., Coren, L. V., and Shatzer, T. (2009) The nucleocapsid region of human immunodeficiency virus type 1 Gag assists in the coordination of assembly and Gag processing: role for RNA-Gag binding in the early stages of assembly. J. Virol. 83, 7718-7727
42. Kaplan, A. H., Manchester, M., and Swanstrom, R. (1994) The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency. J. Virol. 68, 6782-6786
43. Anderson, J., Schiffer, C., Lee, S. K., and Swanstrom, R. (2009) Viral protease inhibitors. Handb. Exp. Pharmacol. 189, 85-110
44. Hoffman, N. G., Schiffer, C. A., and Swanstrom, R. (2003) Covariation of amino acid positions in HIV-1 protease. Virology 314, 536-548 (Pubitemid 37206360)
45. Rhee, S. Y., Taylor, J., Fessel, W. J., Kaufman, D., Towner, W., Troia, P., Ruane, P., Hellinger, J., Shirvani, V., Zolopa, A., and Shafer, R. W. (2010) HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob. Agents Chemother. 54, 4253-4261
46. Watkins, T., Resch, W., Irlbeck, D., and Swanstrom, R. (2003) Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob. Agents Chemother. 47, 759-769 (Pubitemid 36158112)
47. Arribas, J. R., Pulido, F., Delgado, R., Lorenzo, A., Miralles, P., Arranz, A., González-García, J. J., Cepeda, C., Hervás, R., Paño, J. R., Gaya, F., Carcas, A., Montes, M. L., Costa, J. R., and Peña, J. M. (2005) Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J. Acquir. Immune Defic. Syndr. 40, 280-287 (Pubitemid 41533067)
48. Katlama, C., Valantin, M. A., Algarte-Genin, M., Duvivier, C., Lambert-Niclot, S., Girard, P. M., Molina, J. M., Hoen, B., Pakianather, S., Peytavin, G., Marcelin, A. G., and Flandre, P. (2010) Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS 24, 2365-2374
49. Valantin, M. A., Lambert-Niclot, S., Flandre, P., Morand-Joubert, L., Cabiè, A., Meynard, J. L., Ponscarme, D., Ajana, F., Slama, L., Curjol, A., Cuzin, L., Schneider, L., Taburet, A. M., Marcelin, A. G., and Katlama, C. (2012) Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOIANRS 136 study. J. Antimicrob. Chemother. 67, 691-695
50. Gulnik, S. V., Suvorov, L. I., Liu, B., Yu, B., Anderson, B., Mitsuya, H., and Erickson, J. W. (1995) Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 34, 9282-9287
51. Nijhuis, M., Schuurman, R., de Jong, D., Erickson, J., Gustchina, E., Albert, J., Schipper, P., Gulnik, S., and Boucher, C. A. (1999) Increased fitness of drug-resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 13, 2349-2359
52. Partaledis, J. A., Yamaguchi, K., Tisdale, M., Blair, E. E., Falcione, C., Maschera, B., Myers, R. E., Pazhanisamy, S., Futer, O., and Cullinan, A. B. (1995) In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J. Virol. 69, 5228-5235
53. Pazhanisamy, S., Stuver, C. M., Cullinan, A. B., Margolin, N., Rao, B. G., and Livingston, D. J. (1996) Kinetic characterization of human immunodeficiency virus type 1 protease-resistant variants. J. Biol. Chem. 271, 17979-17985 (Pubitemid 26250782)
54. Schock, H. B., Garsky, V. M., and Kuo, L. C. (1996) Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity. J. Biol. Chem. 271, 31957-31963 (Pubitemid 26422220)
55. Prabu-Jeyabalan, M., Nalivaika, E. A., King, N. M., and Schiffer, C. A. (2004) Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease. J. Virol. 78, 12446-12454 (Pubitemid 39458763)
56. Croteau, G., Doyon, L., Thibeault, D., McKercher, G., Pilote, L., and Lamarre, D. (1997) Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J. Virol. 71, 1089-1096 (Pubitemid 27030280)
57. Resch, W., Ziermann, R., Parkin, N., Gamarnik, A., and Swanstrom, R. (2002) Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly. J. Virol. 76, 8659-8666 (Pubitemid 34864060)
58. Zennou, V., Mammano, F., Paulous, S., Mathez, D., and Clavel, F. (1998) Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J. Virol. 72, 3300-3306 (Pubitemid 28175575)
59. Chen, Z., Li, Y., Schock, H. B., Hall, D., Chen, E., and Kuo, L. C. (1995) Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials. J. Biol. Chem. 270, 21433-21436
60. Ho, D. D., Toyoshima, T., Mo, H., Kempf, D. J., Norbeck, D., Chen, C. M., Wideburg, N. E., Burt, S. K., Erickson, J. W., and Singh, M. K. (1994) Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J. Virol. 68, 2016-2020 (Pubitemid 24065777)
61. Kaplan, A. H., Michael, S. F., Wehbie, R. S., Knigge, M. F., Paul, D. A., Everitt, L., Kempf, D. J., Norbeck, D. W., Erickson, J. W., and Swanstrom, R. (1994) Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc. Natl. Acad. Sci. U.S.A. 91, 5597-5601 (Pubitemid 24174375)
62. Mammano, F., Trouplin, V., Zennou, V., and Clavel, F. (2000) Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J. Virol. 74, 8524-8531 (Pubitemid 30666703)
63. Markowitz, M., Mo, H., Kempf, D. J., Norbeck, D. W., Bhat, T. N., Erickson, J. W., and Ho, D. D. (1995) Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J. Virol. 69, 701-706
64. Martinez-Picado, J., Savara, A. V., Sutton, L., and D'Aquila, R. T. (1999) Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J. Virol. 73, 3744-3752 (Pubitemid 29189817)
65. Chang, M. W., and Torbett, B. E. (2011) Accessory mutations maintain stability in drug-resistant HIV-1 protease. J. Mol. Biol. 410, 756-760
66. Bally, F., Martinez, R., Peters, S., Sudre, P., and Telenti, A. (2000) Polymorphism of HIV type 1 Gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors. AIDS Res. Hum. Retroviruses 16, 1209-1213
67. Doyon, L., Croteau, G., Thibeault, D., Poulin, F., Pilote, L., and Lamarre, D. (1996) Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 70, 3763-3769 (Pubitemid 26161824)
68. Koch, N., Yahi, N., Fantini, J., and Tamalet, C. (2001) Mutations in HIV-1 Gag cleavage sites and their association with protease mutations. AIDS 15, 526-528 (Pubitemid 32207574)
69. Mammano, F., Petit, C., and Clavel, F. (1998) Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and Gag coevolution in protease inhibitor-treated patients. J. Virol. 72, 7632-7637 (Pubitemid 28377901)
70. Zhang, Y. M., Imamichi, H., Imamichi, T., Lane, H. C., Falloon, J., Vasudevachari, M. B., and Salzman, N. P. (1997) Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J. Virol. 71, 6662-6670 (Pubitemid 27355324)
71. Parry, C. M., Kohli, A., Boinett, C. J., Towers, G. J., McCormick, A. L., and Pillay, D. (2009) Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1. J. Virol. 83, 9094-9101
72. + T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. J. Infect. Dis. 185, 315-323
73. Mortuza, G. B., Haire, L. F., Stevens, A., Smerdon, S. J., Stoye, J. P., and Taylor, I. A. (2004) High-resolution structure of a retroviral capsid hexameric amino-terminal domain. Nature 431, 481-485 (Pubitemid 39329590)
74. von Schwedler, U. K., Stemmler, T. L., Klishko, V. Y., Li, S., Albertine, K. H., Davis, D. R., and Sundquist, W. I. (1998) Proteolytic refolding of the HIV-1 capsid protein amino terminus facilitates viral core assembly. EMBO J. 17, 1555-1568 (Pubitemid 28119109)
75. Li, S., Hill, C. P., Sundquist, W. I., and Finch, J. T. (2000) Image reconstructions of helical assemblies of the HIV-1 CA protein. Nature 407, 409-413
76. Sticht, J., Humbert, M., Findlow, S., Bodem, J., Müller, B., Dietrich, U., Werner, J., and Kräusslich, H. G. (2005) A peptide inhibitor of HIV-1 assembly in vitro. Nat. Struct. Mol. Biol. 12, 671-677 (Pubitemid 43086272)
77. Ternois, F., Sticht, J., Duquerroy, S., Kräusslich, H. G., and Rey, F. A. (2005) The HIV-1 capsid protein C-terminal domain in complex with a virus assembly inhibitor. Nat. Struct. Mol. Biol. 12, 678-682 (Pubitemid 43086273)
78. Kelly, B. N., Kyere, S., Kinde, I., Tang, C., Howard, B. R., Robinson, H., Sundquist, W. I., Summers, M. F., and Hill, C. P. (2007) Structure of the antiviral assembly inhibitor CAP-1 complex with the HIV-1 CA protein. J. Mol. Biol. 373, 355-366 (Pubitemid 47445574)
79. Tang, C., Loeliger, E., Kinde, I., Kyere, S., Mayo, K., Barklis, E., Sun, Y., Huang, M., and Summers, M. F. (2003) Antiviral inhibition of the HIV-1 capsid protein. J. Mol. Biol. 327, 1013-1020 (Pubitemid 36363708)
80. Blair, W. S., Pickford, C., Irving, S. L., Brown, D. G., Anderson, M., Bazin, R., Cao, J., Ciaramella, G., Isaacson, J., Jackson, L., Hunt, R., Kjerrstrom, A., Nieman, J. A., Patick, A. K., Perros, M., Scott, A. D., Whitby, K., Wu, H., and Butler, S. L. (2010) HIV capsid is a tractable target for small molecule therapeutic intervention. PLoS Pathog. 6, e1001220
81. Shi, J., Zhou, J., Shah, V. B., Aiken, C., and Whitby, K. (2011) Smallmolecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization. J. Virol. 85, 542-549
82. Lemke, C. T., Titolo, S., von Schwedler, U., Goudreau, N., Mercier, J. F., Wardrop, E., Faucher, A. M., Coulombe, R., Banik, S. S., Fader, L., Gagnon, A., Kawai, S. H., Rancourt, J., Tremblay, M., Yoakim, C., Simoneau, B., Archambault, J., Sundquist, W. I., and Mason, S. W. (2012) Distinct effects of two HIV-1 capsid assembly inhibitor families that bind the same site within the N-terminal domain of the viral CA protein. J. Virol. 86, 6643-6655
83. Pettit, S. C., Henderson, G. J., Schiffer, C. A., and Swanstrom, R. (2002) Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease. J. Virol. 76, 10226-10233
84. Coren, L. V., Thomas, J. A., Chertova, E., Sowder, R. C., 2nd, Gagliardi, T. D., Gorelick, R. J., and Ott, D. E. (2007) Mutational analysis of the C-terminal Gag cleavage sites in human immunodeficiency virus type 1. J. Virol. 81, 10047-10054 (Pubitemid 350067708)
85. Li, F., Goila-Gaur, R., Salzwedel, K., Kilgore, N. R., Reddick, M., Matallana, C., Castillo, A., Zoumplis, D., Martin, D. E., Orenstein, J. M., Allaway, G. P., Freed, E. O., and Wild, C. T. (2003) PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc. Natl. Acad. Sci. U.S.A. 100, 13555-13560 (Pubitemid 37444780)
86. Zhou, J., Yuan, X., Dismuke, D., Forshey, B. M., Lundquist, C., Lee, K. H., Aiken, C., and Chen, C. H. (2004) Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation. J. Virol. 78, 922-929 (Pubitemid 38067613)
87. Keller, P. W., Adamson, C. S., Heymann, J. B., Freed, E. O., and Steven, A. C. (2011) HIV-1 maturation inhibitor bevirimat stabilizes the immature Gag lattice. J. Virol. 85, 1420-1428
88. Zhou, J., Huang, L., Hachey, D. L., Chen, C. H., and Aiken, C. (2005) Inhibition of HIV-1 maturation via drug association with the viral Gag protein in immature HIV-1 particles. J. Biol. Chem. 280, 42149-42155 (Pubitemid 43023184)
89. Nguyen, A. T., Feasley, C. L., Jackson, K. W., Nitz, T. J., Salzwedel, K., Air, G. M., and Sakalian, M. (2011) The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles. Retrovirology 8, 101
90. Checkley, M. A., Luttge, B. G., Soheilian, F., Nagashima, K., and Freed, E. O. (2010) The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation. Virology 400, 137-144
91. Rulli, S. J., Jr., Muriaux, D., Nagashima, K., Mirro, J., Oshima, M., Baumann, J. G., and Rein, A. (2006) Mutant murine leukemia virus Gag proteins lacking proline at the N terminus of the capsid domain block infectivity in virions containing wild-type Gag. Virology 347, 364-371
92. Fu, W., Gorelick, R. J., and Rein, A. (1994) Characterization of human immunodeficiency virus type 1 dimeric RNA from wild-type and protease-defective virions. J. Virol. 68, 5013-5018 (Pubitemid 24226568)
93. Shehu-Xhilaga, M., Kraeusslich, H. G., Pettit, S., Swanstrom, R., Lee, J. Y., Marshall, J. A., Crowe, S. M., and Mak, J. (2001) Proteolytic processing of the p2/nucleocapsid cleavage site is critical for human immunodeficiency virus type 1 RNA dimer maturation. J. Virol. 75, 9156-9164 (Pubitemid 32851920)
94. Thomas, J. A., and Gorelick, R. J. (2008) Nucleocapsid protein function in early infection processes. Virus Res. 134, 39-63
95. Sheng, N., and Erickson-Viitanen, S. (1994) Cleavage of p15 protein in vitro by human immunodeficiency virus type 1 protease is RNA-dependent. J. Virol. 68, 6207-6214 (Pubitemid 24294870)
96. Sheng, N., Pettit, S. C., Tritch, R. J., Ozturk, D. H., Rayner, M. M., Swanstrom, R., and Erickson-Viitanen, S. (1997) Determinants of the human immunodeficiency virus type 1 p15NC-RNA interaction that affect enhanced cleavage by the viral protease. J. Virol. 71, 5723-5732 (Pubitemid 27304905)
97. Breuer, S., Chang, M. W., Yuan, J., and Torbett, B. E. (2012) Identification of HIV-1 inhibitors targeting the nucleocapsid protein. J. Med. Chem. 55, 4968-4977
98. Breuer, S., Sepulveda, H., Chen, Y., Trotter, J., and Torbett, B. E. (2011) A cleavage enzyme-cytometric bead array provides biochemical profiling of resistance mutations in HIV-1 Gag and protease. Biochemistry 50, 4371-4381
99. Hermle, J., Anders, M., Heuser, A. M., and Müller, B. (2010) A simple fluorescence based assay for quantification of human immunodeficiency virus particle release. BMC Biotechnol. 10, 32
100. Vogt, V. M., and Eisenman, R. (1973) Identification of a large polypeptide precursor of avian oncornavirus proteins. Proc. Natl. Acad. Sci. U.S.A. 70, 1734-1738
101. King, N. M., Prabu-Jeyabalan, M., Nalivaika, E. A., and Schiffer, C. (2004) Combating susceptibility to drug resistance: lessons from HIV-1 protease. Chem. Biol. 11, 1333-1338 (Pubitemid 39351371)